Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
92 hedge funds and large institutions have $151M invested in Eiger BioPharmaceuticals, Inc. in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 35 increasing their positions, 18 reducing their positions, and 7 closing their positions.
94% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 18
77% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $599K
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
2% more funds holding
Funds holding: 90 → 92 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
23% less capital invested
Capital invested by funds: $196M → $151M (-$45.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.13M |
| 2 |
6CM
683 Capital Management
New York
|
+$1.78M |
| 3 |
DC
Davenport & Co
Richmond,
Virginia
|
+$806K |
| 4 |
Renaissance Technologies
New York
|
+$786K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$541K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$10.5M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.43M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$621K |
| 4 |
Two Sigma Advisers
New York
|
-$515K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$511K |
EIGR Hedge Fund Activity: Q3 2021 in Review
92 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q3 2021, worth a combined $151M — down 23% from $196M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new EIGR positions and 7 closed out — a net gain of 2 holders — while 35 added to existing stakes and 18 trimmed.
The largest buyer was Ameriprise, adding an estimated $3.13M. The largest seller was Vivo Capital, cutting an estimated $10.5M.
- 92 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q3 2021, up from 90 in Q2 2021.
- Funds reported $151M of Eiger BioPharmaceuticals, Inc. stock for Q3 2021, down 23% quarter-over-quarter.
- 9 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q3 2021 and 7 closed out, a net change of +2 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q3 2021 was Ameriprise, an estimated $3.13M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q3 2021 was Vivo Capital, an estimated $10.5M sold.
Based on aggregated 13F filings for Q3 2021.